Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1

APOBEC3介导的HIV-1先天免疫机制

基本信息

  • 批准号:
    8114377
  • 负责人:
  • 金额:
    $ 5万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-08-02 至 2011-08-01
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Recent advances on retroviral research that members of APOBEC3 (A3) subfamily proteins potently blocks replication of retroviruses have opened a new avenue for the development of antiretroviral therapy for human immunodeficiency virus type 1 (HIV-1) infection. This subfamily includes A3A, A3B, A3C, A3DE, A3F, A3G and A3H, which belong to the cytidine deaminase family. They are incorporated into viral particles during viral assembly and disrupt viral reverse transcription to inhibit viral replication. As a counteraction, HIV-1 produces a viral infectivity factor, Vif, to destruct most of the A3 proteins via the proteasomal pathway by serving as a bridge between these proteins and a Cullin 5-based E3 ubiquitin ligase. Although these discoveries are exciting, the field desires for further understanding of how this A3-mediated immunity blocks retroviral infection and why it is so vulnerable to Vif. Our long-term goal is to understand how host factors that contribute to the innate immunity to retroviral infection can be effectively targeted for improved treatment of HIV-1 infection. Our objective in this proposal is to further study the antiretroviral mechanism of A3 protein and the process of their proteasomal degradation triggered by Vif. Our rationale is that a new anti-HIV-1 therapy could be developed if we can find a strategy to express A3 proteins that become insensitive to Vif. We propose the following three specific aims: 1) To study the antiretroviral activity of human A3H; 2) To study the antiretroviral cofactor for A3G; 3) To study the ubiquitin-independent proteasomal degradation of A3G. This project is innovative in that, it offers an opportunity to fully define the architecture of A3-mediated antiretroviral immunity by understanding the function of A3H. It will significantly advance our knowledge by precisely defining the mechanisms related to A3 antiretroviral activity and their degradation in proteasomes. At the completion of this project, it is our expectation that we will be able to not only address these fundamental issues, but also demonstrate the feasibility to employ this immunity to combat HIV-1 infection. Such findings will contribute to a more effective modality for the treatment of HIV infection to be used in conjunction with other chemotherapy and vaccines.
描述(由申请人提供):逆转录病毒研究的最新进展,即APOBEC3(A3)亚家族蛋白质的成员有效阻断逆转录病毒的复制,为人类免疫缺陷病毒1型(HIV-1)感染的抗逆转录病毒疗法的开发开辟了新的途径。该亚家族包括A3A、A3B、A3C、A3DE、A3F、A3G和A3H,它们属于胞苷脱氨酶家族。它们在病毒组装过程中掺入病毒颗粒中,并破坏病毒逆转录以抑制病毒复制。HIV-1产生一种病毒感染因子Vif,作为这些蛋白质和Cullin 5-基E3泛素连接酶之间的桥梁,通过蛋白酶体途径破坏大多数A3蛋白。虽然这些发现令人兴奋,但该领域希望进一步了解这种A3介导的免疫性如何阻止逆转录病毒感染以及为什么它对Vif如此脆弱。我们的长期目标是了解如何有效地靶向有助于逆转录病毒感染的先天免疫的宿主因素,以改善HIV-1感染的治疗。本研究的目的是进一步研究A3蛋白的抗逆转录病毒机制及其在Vif作用下的蛋白酶体降解过程。我们的理论基础是,如果我们能找到一种表达A3蛋白的策略,使其对Vif不敏感,就可以开发一种新的抗HIV-1疗法。我们提出了以下三个具体目标:1)研究人A3H的抗逆转录病毒活性; 2)研究A3G的抗逆转录病毒辅助因子; 3)研究A3G的泛素非依赖性蛋白酶体降解。该项目的创新之处在于,它提供了一个通过了解A3H的功能来充分定义A3介导的抗逆转录病毒免疫的结构的机会。它将通过精确定义与A3抗逆转录病毒活性及其在蛋白酶体中降解相关的机制来显着推进我们的知识。在这个项目完成后,我们希望我们不仅能够解决这些基本问题,而且还能够证明利用这种免疫力来对抗HIV-1感染的可行性。这些发现将有助于与其他化疗和疫苗结合使用更有效的治疗艾滋病毒感染的方式。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

YONG-HUI ZHENG其他文献

YONG-HUI ZHENG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('YONG-HUI ZHENG', 18)}}的其他基金

HIV-1 Env gp160 maturation in the Golgi apparatus
HIV-1 Env gp160 在高尔基体中成熟
  • 批准号:
    10626272
  • 财政年份:
    2023
  • 资助金额:
    $ 5万
  • 项目类别:
The role of SERINC5 in HIV-1 replication
SERINC5 在 HIV-1 复制中的作用
  • 批准号:
    10817137
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
The role of SERINC5 in HIV-1 replication
SERINC5 在 HIV-1 复制中的作用
  • 批准号:
    9974474
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
The role of SERINC5 in HIV-1 replication
SERINC5 在 HIV-1 复制中的作用
  • 批准号:
    10792073
  • 财政年份:
    2019
  • 资助金额:
    $ 5万
  • 项目类别:
Mechanism of HIV-1 Env Degradation by the ERAD pathway
ERAD 途径降解 HIV-1 Env 的机制
  • 批准号:
    9324121
  • 财政年份:
    2016
  • 资助金额:
    $ 5万
  • 项目类别:
To eradicate the HIV macrophage reservoir
根除艾滋病毒巨噬细胞库
  • 批准号:
    8972781
  • 财政年份:
    2015
  • 资助金额:
    $ 5万
  • 项目类别:
Vpr
电压
  • 批准号:
    8705387
  • 财政年份:
    2013
  • 资助金额:
    $ 5万
  • 项目类别:
Vpr
电压
  • 批准号:
    8602711
  • 财政年份:
    2013
  • 资助金额:
    $ 5万
  • 项目类别:
Actions of Vif and APOBEC3 proteins in HIV-1 Replication
Vif 和 A​​POBEC3 蛋白在 HIV-1 复制中的作用
  • 批准号:
    8138198
  • 财政年份:
    2010
  • 资助金额:
    $ 5万
  • 项目类别:
Mechanism of APOBEC3-Mediated Innate Immunity to HIV-1
APOBEC3介导的HIV-1先天免疫机制
  • 批准号:
    7919755
  • 财政年份:
    2009
  • 资助金额:
    $ 5万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 5万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了